Which selective serotonin reuptake inhibitor (SSRI) carries the highest risk of QT interval prolongation?

Highest Risk of QT Prolongation Among SSRIs

Citalopram carries the highest risk of QT prolongation among SSRIs, followed closely by escitalopram, both of which have prompted FDA and EMA dose restrictions specifically due to this cardiac safety concern. 1

Evidence-Based Risk Stratification

The European Heart Journal guidelines explicitly state that both FDA and EMA have limited the maximum recommended doses of citalopram and escitalopram as a direct consequence of QT prolongation studies, with further dose reductions mandated for patients over 60 years of age 1. This regulatory action distinguishes these two agents from all other SSRIs.

Comparative Risk Data

Citalopram demonstrates the most pronounced effect:

• Meta-analysis shows citalopram causes significantly greater QTc prolongation than sertraline, paroxetine, and fluvoxamine 2
• Pharmacovigilance data reveals a reporting odds ratio (ROR) of 3.35 (95% CI 2.90-3.87) for citalopram versus 2.50 (2.11-2.95) for escitalopram 3
• Only citalopram and escitalopram showed statistically significant signals in the WHO global database analysis 3

The rank order from highest to lowest risk is:

1. Citalopram - highest risk, dose-dependent effect
2. Escitalopram - second highest, also dose-dependent
3. Fluoxetine, sertraline, fluvoxamine - similar low risk profile 4
4. Paroxetine - appears to have the lowest risk among all SSRIs 4, with recent 2026 data showing no clinically meaningful QTc prolongation at therapeutic doses 5

Clinical Management Algorithm

For patients requiring SSRI therapy with cardiac risk factors:

• Avoid citalopram and escitalopram in patients with:

  • Baseline QTc >450 ms (men) or >470 ms (women)
  • Congenital long QT syndrome
  • Concurrent use of other QT-prolonging medications
  • Hypokalemia or hypomagnesemia
  • Age >60 years (if higher doses needed)

• Preferred alternatives: Paroxetine demonstrates the most favorable cardiac safety profile, followed by sertraline, fluoxetine, or fluvoxamine 4

• If citalopram/escitalopram must be used:

  • Baseline ECG mandatory
  • Maximum dose: 40 mg citalopram, 20 mg escitalopram
  • Reduce to 20 mg citalopram, 10 mg escitalopram if age >60 years 1
  • Correct electrolyte abnormalities before initiation
  • Follow-up ECG if dose escalation or new QT-prolonging drugs added

Critical Caveats

The guideline evidence emphasizes that QT prolongation with SSRIs is NOT a class effect 3. The pharmacovigilance study definitively shows only citalopram and escitalopram carry significant signals, while other SSRIs do not demonstrate this risk pattern in real-world use.

Important considerations:

• Hypokalemia was present in 17% of cases with severe QTc prolongation 3
• 66% of cases involved concomitant cardiotropic or psychotropic medications 3
• Drug interactions (particularly with CYP2C19 inhibitors like quetiapine) can precipitate severe toxicity even at therapeutic doses 6
• The mean age in SSRI-related cardiac arrest cases was 74 years 1

Despite meta-analysis showing SSRIs as a class cause modest QTc prolongation (+6.10 ms), this finding is driven primarily by citalopram and escitalopram 2. The clinical significance emerges only with these two agents, not with paroxetine, sertraline, fluoxetine, or fluvoxamine at standard doses.